• 1.

    DCCT/EDIC Research Group: Effect of intensive diabetes treatment on albuminuria in type 1 diabetes: Long-term follow-up of the Diabetes Control and Complications Trial and Epidemiology of Diabetes Interventions and Complications study. Lancet Diabetes Endocrinol 2014; 2:793800.

    • Search Google Scholar
    • Export Citation
  • 2.

    Zoungas S, et al.. Follow-up of blood-pressure lowering and glucose control in type 2 diabetes. N Engl J Med 2014; 371:13921406.

  • 3.

    Perkovic V, et al.. Intensive glucose control improves kidney outcomes in patients with type 2 diabetes. Kidney Int 2013; 83:517523.

  • 4.

    Lewis EJ, et al.. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993; 329:14561462.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 5.

    Fried LF, et al.. Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med 2013; 369:18921903.

  • 6.

    Perkovic V, et al.. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 2019; 380:22952306.

  • 1.

    Chan GC and Tang SC. Diabetic nephropathy: Landmark clinical trials and tribulations. Nephrol Dial Transplant 2016; 31:359368.

  • 2.

    Diabetes Control and Complications Trial Research Group, et al.. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329:977986.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 3.

    DCCT/EDIC Research Group. Effect of intensive diabetes treatment on albuminuria in type 1 diabetes: Long-term follow-up of the Diabetes Control and Complications Trial and Epidemiology of Diabetes Interventions and Complications study. Lancet Diabetes Endocrinol 2014; 2:793800.

    • Search Google Scholar
    • Export Citation
  • 4.

    Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352:837853.

    • Search Google Scholar
    • Export Citation
  • 5.

    Perkovic V, et al.. Intensive glucose control improves kidney outcomes in patients with type 2 diabetes. Kidney Int 2013; 83:517523.

  • 6.

    Action to Control Cardiovascular Risk in Diabetes Study, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358:25452559.

    • Search Google Scholar
    • Export Citation
  • 7.

    Lewis EJ, et al.. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993; 329:14561462.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 8.

    Brenner BM, et al.. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345:861869.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 9.

    Lewis EJ, et al.. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345:851860.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 10.

    Haller H, et al.. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N Engl J Med 2011; 364:907917.

  • 11.

    Mann JF, et al.. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): A multicentre, randomised, double-blind, controlled trial. Lancet 2008; 372:547553.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 12.

    Fried LF, et al.. Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med 2013; 369:18921903.

  • 13.

    Parving HH, et al.. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med 2012; 367:22042213.

  • 14.

    de Zeeuw D, et al.. Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease. N Engl J Med 2013; 369:24922503.

  • 15.

    Mann JF, et al.. Avosentan for overt diabetic nephropathy. J Am Soc Nephrol 2010; 21:527535.

  • 16.

    Perkovic V, et al.. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 2019; 380:22952306.

Clinical Trials on Diabetic Kidney Disease: What Have We Learned from Landmark Trials?

  • 1 Vecihi Batuman is with the department of internal medicine and chief, division of nephrology, at Tulane University.
Restricted access
Save